Anterior Cruciate Ligament Transection (ACLT) & Medial Meniscal Tear (MMT) induced Osteoarthritis Modeling & Pharmacodynamics Service
Are you currently facing challenges such as inconsistent disease progression in animal models, poor correlation between preclinical data and clinical outcomes, or the complexity of evaluating pain relief versus structural repair in osteoarthritis? Our ACLT & MMT-Induced Osteoarthritis Modeling & Pharmacodynamics Service helps you obtain highly reproducible, clinically relevant data and validate the efficacy of your disease-modifying OA drugs through surgically precise modeling in rats and rabbits, combined with our high-end multidimensional evaluation platform.
Overview of ACLT & MMT OA Modeling
Osteoarthritis (OA) is a "whole-joint" disease characterized by the progressive destruction of articular cartilage, subchondral bone remodeling, and chronic synovitis. In humans, joint trauma, specifically injuries to the anterior cruciate ligament (ACL) or the medial meniscus, is a primary driver of Post-Traumatic Osteoarthritis (PTOA). The ACLT model simulates chronic joint instability by resecting the ACL, leading to abnormal kinematics and gradual wear. The MMT model, achieved via longitudinal or transverse meniscal tears, creates immediate biomechanical stress and rapid cartilage erosion. These models are the gold standard for studying the pathogenesis of PTOA and evaluating therapeutic interventions aimed at stabilizing the joint or regenerating the chondrocyte matrix.
Fig.1 Workflow of anterior cruciate ligament transection and meniscectomy-induced OA model.1,3
ACLT & MMT Disease Models
Creative Biolabs provides validated surgical protocols to induce OA in rats and rabbits. Our models replicate the human disease spectrum, from early inflammatory flares to late-stage neuropathic pain and full-thickness cartilage ulceration. We focus on high reproducibility, ensuring that your drug candidate is tested against a consistent pathological background.
Evaluation Platform of Our Service
Creative Biolabs utilizes a multi-dimensional analysis suite to provide a holistic view of your therapeutic's impact.
-
Biochemical & Molecular Analysis:
- Cytokine Panels: Measurement via ELISA.
- Catabolic Marker Detection: qPCR and Western Blot.
- Anabolic Tracking: Gene expression of Aggrecan and Type II Collagen.
-
Histopathological Examination:
- Staining Suite: H&E, Safranin-O/Fast Green, and Toluidine Blue.
- Scoring Systems: Modified Mankin Score and OARSI Recommendations.
- IHC: Expression of SOX9, Col-II, and PAR4.
-
Behavioral & Functional Testing:
- Nociception: von Frey hair algesiometry for secondary allodynia.
- Functional Mobility: Gait analysis and hindlimb weight-bearing differential.
- Electrophysiology: Single-unit recordings of joint nociceptor firing.
-
Advanced Imaging & Instrumentation:
- Micro-CT: Assessment of subchondral bone mineral density (BMD) and osteophyte formation.
- Laser Speckle Contrast Analysis: Monitoring joint blood flow and inflammation.
Key Applications
Our models are designed to simulate a variety of clinical indications, including:
- Post-Traumatic Osteoarthritis (PTOA)
- Early-Stage Inflammatory Joint Flares
- Late-Stage Chronic Neuropathic Pain
Creative Biolabs' platform is ideal for evaluating a wide range of therapeutic agents:
- Small Molecules: Non-opioid analgesics, anti-inflammatories, and kinase inhibitors.
- Biologics: Monoclonal antibodies targeting cytokines or nerve growth factors.
- Cell-Based Therapies: Mesenchymal Stem Cells (MSCs) and Autologous Chondrocyte Implantation (ACI).
- Gene Therapies: Lentivirus-mediated gene silencing or overexpression in the synovium.
Why Choose Us?
We offer fully validated protocols specifically in Rat and Rabbit, matching the physiological scale to your research goals.
Our workflow covers everything from initial in vitro chondrogenic differentiation assays to in vivo PD/PK and long-term efficacy studies.
Guided by a PhD-level team with over 20 years of experience, Creative Biolabs ensures rigorous quality management and data integrity.
Work with Us
- Summarize the project requirements and fill in the information collection form.
- Sign a CDA from both parties to further communicate information, such as targets.
- Select an animal model, discuss experimental design, and determine assay parameters.
- Project costing and project schedule forecasting.
- We provide a detailed project plan, including the required sample quantities, methods, and protocols.
- Both parties confirm the project details and start the project.
- Confirm the timeline of the project.
- We provide periodic results and information on the animal's condition.
- We will work together to make project adjustments as necessary.
- We provide a comprehensive project report promptly.
- We arrange transportation for the produced samples.
- We provide a discussion of the project results and help to arrange the next steps.
- Data storage and archiving.
Frequently Asked Questions
-
Q: How do you ensure the reproducibility of the surgical models?
A: At Creative Biolabs, all ACLT and MMT surgeries are performed by senior microsurgeons using standardized protocols. We verify model induction via early-stage imaging and biomarker checks to ensure minimal intra-group variation.
-
Q: Can your platform distinguish between pain relief and structural cartilage repair?
A: Yes. By combining behavioral testing (von Frey) with detailed histopathology (Mankin scoring) and Micro-CT, we can determine if a drug is a symptom-reliever, a DMOAD, or both.
-
Q: What is the typical duration for an OA efficacy study in rabbits?
A: Depending on your goals, studies usually run between 4 and 9 weeks. The MMT model often shows significant cartilage ulceration by week 9, allowing for rapid evaluation.
-
Q: Can we customize the evaluation parameters?
A: Creative Biolabs specializes in tailored study setups. We can integrate specific IHC markers or unique imaging requirements to meet your project's specific needs. Contact our team to discuss your custom project.
Published Data
Objective: To compare the efficacy of targeting Protease-Activated Receptor-4 (PAR4) in reducing pain during early vs. late-stage OA.
Model Used: Rat MMT (Medial Meniscal Transection) and MIA (Monoiodoacetate) models.
Results: By utilizing these high-fidelity models, the study demonstrated that PAR4 expression surges during early-stage inflammation. Notably, the MMT model precisely recaptures early nociceptor sensitization, where PAR4 antagonism effectively suppressed secondary allodynia and joint afferent firing. Conversely, the MIA model revealed a transition to PAR4-independent neuropathic pain in advanced stages. These results validate the models as indispensable translational tools for identifying therapeutic windows, proving that timely intervention is critical for modulating the inflammatory-to-chronic pain switch.
Fig.2 Expression of pAR4 in joint dorsal root ganglion neurons of MMT models.2,3
Creative Biolabs is your trusted partner for high-fidelity Anterior Cruciate Ligament Transection (ACLT) & Medial Meniscal Tear (MMT)-Induced Osteoarthritis Modeling. From precision surgery in rats and rabbits to multidimensional molecular and behavioral analysis, we provide the data you need to bridge the gap between preclinical discovery and clinical success. Reach out to our scientific specialists for a detailed consultation and project quote.
References
- Mende, Lokesh Kumar, Yaswanth Kuthati, and Chih-Shung Wong. "Curcumin and vitamin D supplement attenuates knee osteoarthritis progression in ACLT+ MMx rat model: effect on cartilage protection and pain reduction." Nutrients 17.2 (2025): 349. DOI: https://doi.org/10.3390/nu17020349.
- O'Brien, Melissa S., and Jason J. McDougall. "Targeting Proteinase Activated Receptor-4 Reduces Mechanonociception During the Acute Inflammatory Phase but not the Chronic Neuropathic Phase of Osteoarthritis in Rats." Frontiers in Pharmacology 12 (2021): 756632. DOI: https://doi.org/10.3389/fphar.2021.756632.
- Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only.